Patents by Inventor Hyemi JEON

Hyemi JEON has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pharmaceutical composition comprising organoid and anti-inflammatory agent for preventing or treating inflammatory bowel disease
    Patent number: 11865133
    Abstract: The present disclosure relates to a pharmaceutical composition for preventing or treating inflammatory bowel disease, comprising an intestinal organoid and a TNF? inhibitor. The combination use of the intestinal organoid and TNF? inhibitor according to the present disclosure can alleviate symptoms of inflammatory bowel disease such as weight loss, diarrhea, and bloody stool, and can inhibit fibrosis of the intestinal mucosa due to inflammation. In particular, when the intestinal organoid and the anti-inflammatory TNF? inhibitor are used in combination, the therapeutic effect is significantly superior to that of multiple administrations of the TNF? inhibitor, and thus it can be usefully used as an agent for preventing or treating inflammatory bowel disease.
    Type: Grant
    Filed: September 16, 2022
    Date of Patent: January 9, 2024
    Assignee: ORGANOIDSCIENCES LTD.
    Inventors: Jun-Hyeok Park, Hyemi Jeon, Taegyu Lim, Hayoung Song, Han Kyung Kim, Hyokyung Lee, Ji Hye Tak
  • PHARMACEUTICAL COMPOSITION COMPRISING ORGANOID AND ANTI-INFLAMMATORY AGENT FOR PREVENTING OR TREATING INFLAMMATORY BOWEL DISEASE
    Publication number: 20230210886
    Abstract: The present disclosure relates to a pharmaceutical composition for preventing or treating inflammatory bowel disease, comprising an intestinal organoid and a TNF? inhibitor. The combination use of the intestinal organoid and TNF? inhibitor according to the present disclosure can alleviate symptoms of inflammatory bowel disease such as weight loss, diarrhea, and bloody stool, and can inhibit fibrosis of the intestinal mucosa due to inflammation. In particular, when the intestinal organoid and the anti-inflammatory TNF? inhibitor are used in combination, the therapeutic effect is significantly superior to that of multiple administrations of the TNF? inhibitor, and thus it can be usefully used as an agent for preventing or treating inflammatory bowel disease.
    Type: Application
    Filed: September 16, 2022
    Publication date: July 6, 2023
    Applicant: ORGANOIDSCIENCES LTD.
    Inventors: Jun-Hyeok PARK, Hyemi JEON, Taegyu LIM, Hayoung SONG, Han Kyung KIM, Hyokyung LEE, Ji Hye TAK